- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: DPT vaccine.
Displaying page 1 of 1.
EudraCT Number: 2014-005282-78 | Sponsor Protocol Number: 114720 | Start Date*: 2016-08-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase IV, randomised, open-label, controlled study to assess the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids™ when co-a... | |||||||||||||
Medical condition: Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV). | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002944-18 | Sponsor Protocol Number: BIA-HDMP-201 | Start Date*: 2016-11-14 |
Sponsor Name:Bial Industrial Farmacéutica S.A. | ||
Full Title: MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC R... | ||
Medical condition: The disease under study is allergic rhinoconjunctivitis secondary to sensitization to DPT and DF. Included in the study are patients diagnosed with that disease who also have associated mild asthma... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001714-26 | Sponsor Protocol Number: CYD29 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001694-14 | Sponsor Protocol Number: CYD08 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001713-26 | Sponsor Protocol Number: CYD28 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001737-88 | Sponsor Protocol Number: CYD57 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Long-Term Safety Follow-Up of Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001715-39 | Sponsor Protocol Number: CYD30 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001736-11 | Sponsor Protocol Number: CYD33 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001711-40 | Sponsor Protocol Number: CYD24 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001707-53 | Sponsor Protocol Number: CYD13 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001709-41 | Sponsor Protocol Number: CYD22 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001716-19 | Sponsor Protocol Number: CYD15 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001708-24 | Sponsor Protocol Number: CYD14 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001534-29 | Sponsor Protocol Number: CYD05 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in the Philippines | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001706-17 | Sponsor Protocol Number: CYD06 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in Mexico | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001717-11 | Sponsor Protocol Number: CYD32 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001710-25 | Sponsor Protocol Number: CYD23 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004177-16 | Sponsor Protocol Number: B1841007 | Start Date*: 2015-04-09 |
Sponsor Name:Pfizer Japan, Inc. | ||
Full Title: A Phase 4, Randomized, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. | ||
Medical condition: Prevention of disease caused by a type of bacteria called Streptococcus pneumoniae (pneumococcal disease). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-003710-16 | Sponsor Protocol Number: 112640 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, open, controlled study in healthy Japanese children to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for active immunization against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 2 years of age) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004181-21 | Sponsor Protocol Number: B1851056 | Start Date*: 2015-04-09 | |||||||||||
Sponsor Name:Pfizer Japan, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-L... | |||||||||||||
Medical condition: Prevention of disease caused by a type of bacteria called Streptococcus pneumoniae (pneumococcal disease). | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
